- If Socialist Candidate Bernie Sanders Was President, Here's What Would Happen to the U.S. Economy
- Hillary Clinton and Bernie Sanders Might Run for President Together
- Here's Why You Should Buy Tesla Right Now
- How Obamacare is Cutting Your Salary -- And Your Vacation Budget
- If Hillary Clinton Is Elected President, Here's What Will Happen to the U.S. Economy
Health care stocks are getting hit hard by the stock market turbulence of 2016. But these seven health care companies are worth owning, says Credit Suisse.
U.S. stocks ended near session lows as Wall Street suffered a market-wide selloff on Friday.
This once high-flying biotech stock has hit bad times that aren't likely to abate anytime soon. Here are the reasons for shunning this erstwhile Wall Street darling.
The rising cost of health care should have a positive impact on CVS' bottom line.
Apple’s quarterly earnings report failed to inspire Wall Street traders last week, but investors should remain energetic about the tech giant’s stock.
By Bruce Kamich
Assuming CI closes below $127, the next chart support is not until the $105 area.
Shares of Siemens dropped over 14% in 2015, but a recent earnings report has given the German turbine-maker’s stock a jolt.
Someone needs to send MannKind executives a primer on the uses of Twitter hashtags.
Wall Street couldn't make up its mind with stocks veering wildly between heavy losses and mild gains for much of the session on Wednesday.
Even in this choppy market, opportunities abound. A compelling buy is insurance giant Aetna, which has enjoyed an earnings growth streak with no signs of abating.
Surgical robotics companies could be set to see some big benefits, according to Balcones Investment Research's Randy Bateman.
Intel’s investment in the Internet of Things appears to be paying off, with new products being launched this year and revenue growing for the division.
The time is ripe for these three biotechnology exchange-traded funds, which are posting robust double-digit gains while the broader markets falter.
Here are five key takeaways from the health care giant's latest earnings report.
Foster City, Calif.-based biotech giant Gilead announced a new $12 billion share repurchase plan on Tuesday night in conjunction with fourth-quarter earnings.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.